Detalhe da pesquisa
1.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
N Engl J Med
; 386(18): 1687-1699, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35334197
2.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Br J Dermatol
; 187(4): 531-538, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442530
3.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484697
4.
Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
J Am Acad Dermatol
; 86(2): 359-364, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474079
5.
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
J Cutan Med Surg
; 26(4): 377-385, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354410
6.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
J Am Acad Dermatol
; 85(1): 62-70, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600915
7.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
8.
Clinical Relevance of Skin Pain in Atopic Dermatitis.
J Drugs Dermatol
; 19(10): 921-926, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026764
9.
Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.
J Drugs Dermatol
; 19(10): 943-948, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026770
10.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10143): 222-231, 2018 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043749
11.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
J Am Acad Dermatol
; 80(4): 913-921.e9, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410014
12.
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Ann Rheum Dis
; 76(11): 1853-1861, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28798049
13.
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Ann Rheum Dis
; 76(4): 694-700, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799159
14.
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 239, 2017 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29212515
15.
Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 237, 2017 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29208004
16.
Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
Health Qual Life Outcomes
; 14(1): 139, 2016 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716283
17.
Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort.
BMJ Open
; 12(2): e053137, 2022 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173000
18.
Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7
Eur J Dermatol
; 32(2): 237-243, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35866910
19.
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
J Dermatolog Treat
; 33(4): 2057-2062, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34176407
20.
Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
Arthritis Care Res (Hoboken)
; 73(4): 481-488, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31961494